Cialis Patent Expiration

Cialis is a drug owned by Eli Lilly And Co. It is protected by 9 US drug patents filed from 2013 to 2018 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 15, 2021. Details of Cialis's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6821975

(Pediatric)

Beta-carboline drug products
May, 2021

(3 years ago)

Expired
US6821975 Beta-carboline drug products
Nov, 2020

(4 years ago)

Expired
US6943166

(Pediatric)

Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
Oct, 2020

(4 years ago)

Expired
US7182958

(Pediatric)

β-carboline pharmaceutical compositions
Oct, 2020

(4 years ago)

Expired
US6943166 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
Apr, 2020

(4 years ago)

Expired
US7182958 β-carboline pharmaceutical compositions
Apr, 2020

(4 years ago)

Expired
US5859006

(Pediatric)

Tetracyclic derivatives; process of preparation and use
May, 2018

(6 years ago)

Expired
US5859006 Tetracyclic derivatives; process of preparation and use
Nov, 2017

(7 years ago)

Expired
US6140329 Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence
Jul, 2016

(8 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cialis's patents.

Given below is the list of recent legal activities going on the following patents of Cialis.

Activity Date Patent Number
Patent litigations
Review Certificate Mailed 27 Jun, 2019 US6821975 (Litigated)
Review Certificate Mailed 26 Jun, 2019 US7182958 (Litigated)
Review Certificate 12 Jun, 2019 US6821975 (Litigated)
Review Certificate 12 Jun, 2019 US7182958 (Litigated)
Request for Trial Denied 07 Dec, 2018 US6943166 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 16 Jul, 2018 US7182958 (Litigated)
Petition Requesting Trial 07 Jun, 2018 US6943166 (Litigated)
Termination or Final Written Decision 27 Oct, 2017 US6943166 (Litigated)
Termination or Final Written Decision 03 Oct, 2017 US6943166 (Litigated)
Termination or Final Written Decision 16 Aug, 2017 US6943166 (Litigated)


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Cialis and ongoing litigations to help you estimate the early arrival of Cialis generic.

Cialis's Litigations

Cialis been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 13, 2015, against patent number US7182958. The petitioner Actelion Pharmaceuticals Ltd, challenged the validity of this patent, with ICOS Corporation as the respondent. Click below to track the latest information on how companies are challenging Cialis's patents.

Last updated on December 17, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6943166 June, 2018 Terminated-Denied
(07 Dec, 2018)
ICOS Corporation Aquestive Therapeutics, Inc.
US6943166 July, 2017 Terminated-Settled
(27 Oct, 2017)
ICOS Corporation Dr. Reddy's Laboratories, Inc.
US6943166 July, 2017 Terminated-Settled
(03 Oct, 2017)
ICOS Corporation Argentum Pharmaceuticals LLC
US6943166 November, 2016 Terminated-Settled
(16 Aug, 2017)
ICOS Corporation Mylan Pharmaceuticals Inc.
US6943166 December, 2016 Terminated-Denied
(03 Jul, 2017)
ICOS Corporation MonoSol Rx, LLC
US6943166 February, 2016 Terminated-Denied
(01 Sep, 2016)
ICOS Corporation IntelGenx Corp.
US6821975 January, 2015 FWD Entered
(03 Aug, 2016)
ICOS Corporation Actelion Pharmaceuticals Ltd
US7182958 January, 2015 FWD Entered
(03 Aug, 2016)
ICOS Corporation Actelion Pharmaceuticals Ltd


FDA has granted some exclusivities to Cialis. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Cialis, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Cialis.

Exclusivity Information

Cialis holds 4 exclusivities. All of its exclusivities have expired in 2021. Details of Cialis's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-641) Oct 06, 2014
New Indication(I-642) Oct 06, 2014
M(M-219) Feb 15, 2021
Pediatric Exclusivity(PED) Aug 15, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Cialis is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cialis's family patents as well as insights into ongoing legal events on those patents.

Cialis's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Cialis's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 15, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Cialis Generic API suppliers:

Tadalafil is the generic name for the brand Cialis. 29 different companies have already filed for the generic of Cialis, with Macleods Pharms Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cialis's generic

How can I launch a generic of Cialis before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Cialis's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Cialis's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Cialis -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
2.5 mg 14 Oct, 2008 1 22 May, 2018 19 Nov, 2020 Eligible
5 mg, 10 mg and 20 mg 21 Nov, 2007 1 22 May, 2018 19 Nov, 2020 Eligible

Alternative Brands for Cialis

Cialis which is used for treating erectile dysfunction and sexual dysfunction., has several other brand drugs in the same treatment category and using the same active ingredient (Tadalafil). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bayer Hlthcare
Staxyn Used for treating erectile dysfunction.
Levitra Used for treating erectile dysfunction.
Metuchen Pharms
Stendra Used for treating erectile dysfunction.
Mylan Speciality Lp
Muse Used for treating erectile dysfunction.
Viatris
Viagra Used for treating erectile dysfunction.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Tadalafil. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Actelion
Opsynvi
Cmp Dev Llc
Tadliq
Eli Lilly Co
Adcirca


Apart from brand drugs containing the same ingredient, some generics have also been filed for Tadalafil, Cialis's active ingredient. Check the complete list of approved generic manufacturers for Cialis





About Cialis

Cialis is a drug owned by Eli Lilly And Co. It is used for treating erectile dysfunction and sexual dysfunction. Cialis uses Tadalafil as an active ingredient. Cialis was launched by Lilly in 2003.

Approval Date:

Cialis was approved by FDA for market use on 21 November, 2003.

Active Ingredient:

Cialis uses Tadalafil as the active ingredient. Check out other Drugs and Companies using Tadalafil ingredient

Treatment:

Cialis is used for treating erectile dysfunction and sexual dysfunction.

Dosage:

Cialis is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
2.5MG TABLET Discontinued ORAL
20MG TABLET Prescription ORAL
10MG TABLET Prescription ORAL
5MG TABLET Prescription ORAL